This is the text extract for November Tender Notification; Contact: Notifications, browse documents here.

---

30 November 2011

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2009/10 Invitation to Tender, dated 4 December 2009. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A456727 - qA18036

Page 1 of 4

---

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Eye drops 0.2%; 5 ml OP, 1 dropper Inj 50 mcg per ml, 1 ml; 5 ampoules Current New subsidy subsidy and and price price $7.93 $25.65 (Hospira) $43.50 (Novartis) $48.50 (Hospira) $81.00 (Novartis) $175.00 (Hospira) $399.00 (Novartis) $6.45 Sole supply brand (Supplier) Arrow-Brimonidine (Arrow) Octreotide MaxRx (Max Health) Date of listing/subsidy change for tender winning brand 1 May 2012 Date of reference pricing of other listed brands 1 July 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 October 2012 AFT (AFT) Hospira (Hospira) Sandostatin (Novartis) Hospira (Hospira) Sandostatin (Novartis) Hospira (Hospira) Sandostatin (Novartis)

Brimonidine tartrate Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Octreotide (somatostatin analogue)

$19.24

1 June 2012

1 August 2012

1 November 2012

Inj 100 mcg per ml, 1 ml; 5 ampoules

$36.38

Octreotide MaxRx (Max Health)

1 June 2012

1 August 2012

1 November 2012

Inj 500 mcg per ml, 1 ml; 5 ampoules

$131.25

Octreotide MaxRx (Max Health)

1 June 2012

1 August 2012

1 November 2012

A4567270317 - qA18036

Page 2 of 4

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical Name Imipenem with cilastatin Presentation; Pack size and type Inj 500 mg with cilastatin 500 mg; 1 vial Current pack price $21.61 New pack price $18.37 Hospital Supply Brand (Supplier) Primaxin (MSD) DV Limit 1% Date of price change 1 January 2012 Hospital Supply Status date 1 March 2012

The decisions were as follows:

3.

Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Eye drops 0.2%; 5 ml OP, 1 dropper Inj 500 mg; 1 glass vial Inj 1 g; 1 glass vial Inj 50 mcg per ml, 1 ml; 5 ampoules Inj 100 mcg per ml, 1 ml; 5 ampoules Inj 500 mcg per ml, 1 ml; 5 ampoules Current pack price $7.93 $25.50 $50.50 $25.65 New pack price $6.45 $10.50 $21.00 $19.24 Hospital Supply Brand (Supplier) Arrow-Brimonidine (Arrow) Penembact (InterPharma) Penembact (InterPharma) Octreotide MaxRx (Max Health) Octreotide MaxRx (Max Health) Octreotide MaxRx (Max Health) DV Limit 1% 1% 1% 1% Date of listing/price change for tender winning brand 1 May 2012 1 January 2012 1 January 2012 1 June 2012 Hospital Supply Status date (and delisting of other listed brands) 1 July 2012 1 March 2012 1 March 2012 1 August 2012 Brand (Supplier) to be delisted AFT (AFT) Merrem (AstraZeneca) Merrem (AstraZeneca) Hospira (Hospira) Hospira (Hospira) Hospira (Hospira)

The decisions were as follows:

Chemical Name

Brimonidine tartrate Meropenem Meropenem Octreotide (somatostatin analogue) Octreotide (somatostatin analogue) Octreotide (somatostatin analogue)

$48.50

$36.38

1%

1 June 2012

1 August 2012

$175.00

$131.25

1%

1 June 2012

1 August 2012

A4567270317 - qA18036

Page 3 of 4

---

2009/10 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2013 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Tab 2.5 mg; 30 tablets Tab 5 mg; 30 tablets Tab 10 mg; 30 tablets Subsidy and price $3.88 $4.74 $9.18 Sole supply brand (Supplier) Bosvate (Douglas) Bosvate (Douglas) Bosvate (Douglas) Date of listing 1 April 2012 1 April 2012 1 April 2012 Sole Subsidised Supply date 1 July 2012 1 July 2012 1 July 2012

Chemical name *Bisoprolol Fumarate *Bisoprolol Fumarate *Bisoprolol Fumarate

*Bisoprolol Fumarate will also be listed in Section H of the Pharmaceutical Schedule but will not have Hospital Supply Status.

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A4567270317 - qA18036

Page 4 of 4